Theravance Biopharma Inc (TBPH)

7.99
0.00(0.00%)
After Hours
7.99
-0.01(-0.12%)
- Real-time Data
  • Volume:
    471,188
  • Bid/Ask:
    7.18/7.99
  • Day's Range:
    7.97 - 8.14

TBPH Overview

Prev. Close
7.99
Day's Range
7.97-8.14
Revenue
64.16M
Open
8.08
52 wk Range
6.1-22.74
EPS
-4.11
Volume
471,188
Market Cap
587.03M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,280,769
P/E Ratio
-
Beta
0.82
1-Year Change
-56.88%
Shares Outstanding
73,470,151
Next Earnings Date
Nov 09, 2021
What is your sentiment on Theravance Biopharma Inc?
or
Market is currently closed. Voting is open during market hours.

Theravance Biopharma Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellSellStrong Sell
Technical IndicatorsStrong SellStrong SellBuyStrong BuyStrong Sell
SummaryStrong SellStrong SellNeutralNeutralStrong Sell

Theravance Biopharma Inc Company Profile

Theravance Biopharma Inc Company Profile

Employees
359

Theravance Biopharma, Inc. is a biopharmaceutical company, which is focused on the discovery, development and commercialization of organ-selective medicines. The Company develops transformational medicines to improve the lives of patients suffering from serious illnesses. The Company’s research is focused in the areas of inflammation and immunology. It applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The Company is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution. The revefenacin is a long-acting muscarinic antagonist (LAMA), which is in development for the treatment of patients with chronic obstructive pulmonary disease (COPD). Its programs also include TD-0903, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.

Read More
  • lets hope
    0
    • Sundial growers next week 1,5 $
      2
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.